From code on a screen to the atomic reconstruction of the foundations of life: Why is global pharma’s rush into China’s “AI nanodelivery” considered the most groundbreaking milestone in AI for Science?
For years, many people’s impression of AI drug discovery was still stuck at concept presentations about generating small-molecule compounds. But the real bottleneck in physical drug development isn’t design—it’s “delivery.”
Whether mRNA vaccines or nucleic acid-based gene therapies, 90% are captured and swallowed by the liver after entering the bloodstream, making it virtually impossible to precisely cross the blood-brain barrier or target vital organs such as the lungs and heart. Traditionally, finding effective LNPs (lipid nanoparticles) has relied entirely on chemists screening candidates through trial and error—a process that takes 3–5 years.
Now, generative AI and molecular dynamics modeling have rewritten the rules from the ground up. By reverse-engineering designs from libraries of tens of millions of autonomously generated lipids, they have compressed the development of targeted nanodelivery from years to 2–3 months and enabled tissue-specific delivery to eight major tissue types—prompting multinational giants to commit a staggering $1.1 billion to partnerships.
From computing chips to nanocarriers, technological paradigms are steadily breaking through the physical and biological limits of the real world.
$BTC $BNB #AI #Science #BioTech
For years, many people’s impression of AI drug discovery was still stuck at concept presentations about generating small-molecule compounds. But the real bottleneck in physical drug development isn’t design—it’s “delivery.”
Whether mRNA vaccines or nucleic acid-based gene therapies, 90% are captured and swallowed by the liver after entering the bloodstream, making it virtually impossible to precisely cross the blood-brain barrier or target vital organs such as the lungs and heart. Traditionally, finding effective LNPs (lipid nanoparticles) has relied entirely on chemists screening candidates through trial and error—a process that takes 3–5 years.
Now, generative AI and molecular dynamics modeling have rewritten the rules from the ground up. By reverse-engineering designs from libraries of tens of millions of autonomously generated lipids, they have compressed the development of targeted nanodelivery from years to 2–3 months and enabled tissue-specific delivery to eight major tissue types—prompting multinational giants to commit a staggering $1.1 billion to partnerships.
From computing chips to nanocarriers, technological paradigms are steadily breaking through the physical and biological limits of the real world.
$BTC $BNB #AI #Science #BioTech
